Cell and Gene Therapy (CGT) Pharmaceuticals Market is projected to reach USD $ Billion in 2025, at a $% CAGR by driving industry size, share, segments research, top cpany analysis, trends and forecast report 2025 to 2031.

Cell and Gene Therapy (CGT) Pharmaceuticals Market Growth and Outlook 2025-2031

The global Cell and Gene Therapy (CGT) Pharmaceuticals market size is predicted to grow from US$ 18030 million in 2025 to US$ 52790 million in 2031; it is expected to grow at a CAGR of 19.6% from 2025 to 2031.Cell and Gene Therapy (CGT) drugs are a class of innovative treatments that treat diseases by changing the patient's cells or genes. Specifically, CGT drugs usually include: 1. Gene therapy: by introducing, deleting or repairing genes into the patient's cells, the purpose is to correct diseases caused by genetic defects or mutations. For example, gene therapy can deliver normal genes to patients through viral vectors to replace missing or defective genes.2. Cell therapy: by changing or enhancing the patient's own cells and then re-injecting them into the body for treatment. Common cell therapies include using immune cells (such as CAR-T cells) to treat cancer or using stem cells to repair damaged tissues.United States market for Cell and Gene Therapy (CGT) Pharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.China market for Cell and Gene Therapy (CGT) Pharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.Europe market for Cell and Gene Therapy (CGT) Pharmaceuticals is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.Global key Cell and Gene Therapy (CGT) Pharmaceuticals players cover Vericel, Castle Creek, Terumo, Nipro, BioCardia, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.LPI (LP Information)' newest research report, the &ldquo;Cell and Gene Therapy (CGT) Pharmaceuticals Industry Forecast&rdquo; looks at past sales and reviews total world Cell and Gene Therapy (CGT) Pharmaceuticals sales in 2024, providing a comprehensive analysis by region and market sector of projected Cell and Gene Therapy (CGT) Pharmaceuticals sales for 2025 through 2031. With Cell and Gene Therapy (CGT) Pharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell and Gene Therapy (CGT) Pharmaceuticals industry.This Insight Report provides a comprehensive analysis of the global Cell and Gene Therapy (CGT) Pharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&amp;A activity. This report also analyses the strategies of leading global companies with a focus on Cell and Gene Therapy (CGT) Pharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms&rsquo; unique position in an accelerating global Cell and Gene Therapy (CGT) Pharmaceuticals market.This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell and Gene Therapy (CGT) Pharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell and Gene Therapy (CGT) Pharmaceuticals.This report presents a comprehensive overview, market shares, and growth opportunities of Cell and Gene Therapy (CGT) Pharmaceuticals market by product type, application, key players and key regions and countries.Segmentation by Type:&nbsp;&nbsp;&nbsp; Cell Therapy Drugs &nbsp;&nbsp;&nbsp; Gene Therapy DrugsSegmentation by Application:&nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Clinic &nbsp;&nbsp;&nbsp; OtherThis report also splits the market by region:&nbsp;&nbsp;&nbsp; Americas&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil&nbsp;&nbsp;&nbsp; APAC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia&nbsp;&nbsp;&nbsp; Europe&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia&nbsp;&nbsp;&nbsp; Middle East &amp; Africa&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC CountriesThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.&nbsp;&nbsp;&nbsp; Vericel &nbsp;&nbsp;&nbsp; Castle Creek &nbsp;&nbsp;&nbsp; Terumo &nbsp;&nbsp;&nbsp; Nipro &nbsp;&nbsp;&nbsp; BioCardia &nbsp;&nbsp;&nbsp; Sanpower Group &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Gilead Sciences, Inc./Fosun Kite &nbsp;&nbsp;&nbsp; BMS &nbsp;&nbsp;&nbsp; JW (Cayman) Therapeutics &nbsp;&nbsp;&nbsp; Legend Biotech Corp./Johnson &amp; Johnson &nbsp;&nbsp;&nbsp; Innovent Biologics, Inc./IASO Biotherapeutics &nbsp;&nbsp;&nbsp; Juventas/CASI &nbsp;&nbsp;&nbsp; CARsgen Therapeutics Holdings &nbsp;&nbsp;&nbsp; Huadong Medicine &nbsp;&nbsp;&nbsp; inno.N &nbsp;&nbsp;&nbsp; lovance &nbsp;&nbsp;&nbsp; Mesoblast &nbsp;&nbsp;&nbsp; Takeda &nbsp;&nbsp;&nbsp; Pierre fabre &nbsp;&nbsp;&nbsp; Aurion Biotech &nbsp;&nbsp;&nbsp; Gamida Cell &nbsp;&nbsp;&nbsp; CellTrans &nbsp;&nbsp;&nbsp; SiBiono Gene Technology &nbsp;&nbsp;&nbsp; Ferring &nbsp;&nbsp;&nbsp; Kyowa Kirin &nbsp;&nbsp;&nbsp; uniQure &nbsp;&nbsp;&nbsp; Roche &nbsp;&nbsp;&nbsp; PTC Therapeutics &nbsp;&nbsp;&nbsp; BioMarin &nbsp;&nbsp;&nbsp; CSL &nbsp;&nbsp;&nbsp; Sarepta &nbsp;&nbsp;&nbsp; AnGes &nbsp;&nbsp;&nbsp; bluebird bio &nbsp;&nbsp;&nbsp; Krystal Biotech

Report	Global Cell and Gene Therapy (CGT) Pharmaceuticals Market Growth (Status and Outlook) 2025-2031
Selected License	Single ID:LPI3475

Buyer Information

Order Summary